Praxis Precision Medicines (PRAX) Earnings Date, Estimates & Call Transcripts

$54.54
+0.38 (+0.70%)
(As of 05/3/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 9Estimated
Actual EPS
(Mar. 5)
-$2.97 Beat By $0.08
Consensus EPS
(Mar. 5)
-$3.05
Skip Charts & View Estimated and Actual Earnings Data

PRAX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PRAX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Praxis Precision Medicines Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20243($2.03)($0.27)($1.34)
Q2 20243($2.20)($0.25)($1.39)
Q3 20243($2.23)($0.25)($1.41)
Q4 20243($2.25)($0.25)($1.43)
FY 202412($8.71)($1.02)($5.58)

PRAX Earnings Date and Information

Praxis Precision Medicines last released its earnings results on March 5th, 2024. The reported ($2.97) EPS for the quarter, topping analysts' consensus estimates of ($3.05) by $0.08. The company earned $0.52 million during the quarter, compared to analyst estimates of $0.30 million. Praxis Precision Medicines has generated ($23.66) earnings per share over the last year (($23.66) diluted earnings per share). Earnings for Praxis Precision Medicines are expected to decrease in the coming year, from ($8.64) to ($9.42) per share. Praxis Precision Medicines has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off prior year's report dates.

Praxis Precision Medicines Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/9/2024
Estimated)
------- 
3/5/2024Q4 2023($3.05)($2.97)+$0.08($2.97)$0.30 million$0.52 million
11/7/2023Q3 2023($5.25)($2.70)+$2.55($0.18)-$0.47 million
8/9/2023Q2 2023($9.90)($7.35)+$2.55($0.49)-$0.78 million
5/11/2023Q1 2023($11.25)($10.65)+$0.60($0.71)-$0.68 million
2/7/2023Q4 2022($10.95)($13.05)($2.10)($0.87)--
11/9/2022Q3 2022($13.80)($14.40)($0.60)($0.96)--
8/8/2022Q2 2022($19.50)($19.80)($0.30)($1.32)--
5/9/2022Q1 2022($19.35)($22.65)($3.30)($1.51)--      
2/28/2022Q4 2021($16.20)($19.50)($3.30)($1.30)--    
11/3/2021Q3 2021($13.95)($15.00)($1.05)($1.00)--  
8/16/2021Q2 2021($10.20)($13.20)($3.00)($0.88)--
5/11/2021Q1($11.1450)($10.65)+$0.4950($0.71)--

Praxis Precision Medicines Earnings - Frequently Asked Questions

When is Praxis Precision Medicines's earnings date?

Praxis Precision Medicines has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off last year's report dates. Learn more on PRAX's earnings history.

Did Praxis Precision Medicines beat their earnings estimates last quarter?

In the previous quarter, Praxis Precision Medicines (NASDAQ:PRAX) reported ($2.97) earnings per share (EPS) to beat the analysts' consensus estimate of ($3.05) by $0.08. Learn more on analysts' earnings estimate vs. PRAX's actual earnings.

How much revenue does Praxis Precision Medicines generate each year?

Praxis Precision Medicines (NASDAQ:PRAX) has a recorded annual revenue of $2.45 million.

How much profit does Praxis Precision Medicines generate each year?

Praxis Precision Medicines (NASDAQ:PRAX) has a recorded net income of -$123.28 million. PRAX has generated -$23.66 earnings per share over the last four quarters.

What is Praxis Precision Medicines's EPS forecast for next year?

Praxis Precision Medicines's earnings are expected to decrease from ($8.64) per share to ($9.42) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:PRAX) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners